Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2010 - 2026)

Vanda Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $273000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $273000.0, up 18.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 29.52% YoY), and the FY2025 annual result was $1.1 million, up 28.41% from the prior year.
• Depreciation & Amortization (CF) came in at $273000.0 for Q1 2026 at Vanda Pharmaceuticals, down from $304000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $323000.0 in Q1 2022 to a low of $185000.0 in Q4 2023.
• The 5-year median for Depreciation & Amortization (CF) is $267000.0 (2022), against an average of $255000.0.
• Across the five-year window, Depreciation & Amortization (CF) slumped 33.11% in 2023 and soared 39.35% in 2025, its largest moves.
• Vanda Pharmaceuticals' Depreciation & Amortization (CF) stood at $267000.0 in 2022, then plunged by 30.71% to $185000.0 in 2023, then increased by 19.46% to $221000.0 in 2024, then jumped by 37.56% to $304000.0 in 2025, then slipped by 10.2% to $273000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $273000.0 (Q1 2026), $304000.0 (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.